Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pantoprazole + levofloxacin + azithromycin is a combination of three pharmaceutical agents, each with distinct mechanisms of action. Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly inhibiting the (H+, K+)-ATPase enzyme in gastric parietal cells, leading to reduced stomach acidity[7]. Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and cell division, resulting in bactericidal activity[2][8]. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation and thus preventing bacterial growth[6]. This combination may be used off-label for certain infections or as part of regimens targeting resistant or mixed infections; however, it is not an established fixed-dose combination product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pantoprazole + levofloxacin + azithromycin.